Cancer clinical trials in the region Auvergne-Rhône-Alpes

477 currently recruiting clinical trials
Region Auvergne-Rhône-Alpes

Phase 2 Sarcoma and GIST #NCT04698785
Required histologic types
Bone sarcoma
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None 1
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
8 recruiting sites
Centre Léon Bérard
Phase 2 Acute leukemia #NCT05260528 #2022-500295-60-00
Required histologic types
Acute myeloid leukemia (AML)
Required number of previous lines of therapy
None
31 recruiting sites
Centre Hospitalier Universitaire de Nice
Phase 2 Sarcoma and GIST #NCT04874311 #2020-005703-39
Required histologic types
Soft tissue sarcoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
3 recruiting sites
Institut Bergonié
Phase 2 Pancreas cancer Sarcoma and GIST #NCT05732831 #2022-502645-99-00
Required histologic types
Bone sarcoma Soft tissue sarcoma
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MTAP
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Tango Therapeutics
Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT05489211 #2022-000776-19
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at localized stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Antibody Drug Conjugates (ADC)
2 recruiting sites
AstraZeneca
Phase 2 Prostate cancer #NCT06172478 #2023-507641-29-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Daiichi Sankyo
Phase 2 Lung cancer #NCT06172478 #2023-507641-29-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded genetic anomalies
ALK BRAF EGFR HER2 KRAS G12C MET NTRK-1/2/3 RET ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Daiichi Sankyo
Phase 2 Head and neck cancer #NCT06172478 #2023-507641-29-00
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Daiichi Sankyo
Phase 2 Stomach and esophageal cancer #NCT05476796
Required histologic types
Stomach Oesogastric junction Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required CPS scores
CPS Positive (1 <= X < 5) CPS Positive (5 <= X < 10) CPS Positive (X >= 10)
Excluded genetic anomalies
HER2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
25 recruiting sites
UNICANCER
Phase 2 Stomach and esophageal cancer #NCT06846346 #2025-520694-39-00
Required histologic types
Stomach Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Claudin 18.2 HER2
Required number of previous lines of therapy for current stage of disease
1
Required CPS scores
CPS Positive (1 <= X < 5) CPS Positive (5 <= X < 10) CPS Positive (X >= 10)
Excluded genetic anomalies
MSI/dMMR
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
UNICANCER